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Abstract
Rationale and Objectives: There is evidence that drug addiction is associated with increased physiological and
psychological responses to stress. In this pilot functional magnetic resonance imaging (fMRI) study we assessed whether a
prototype behavioral addiction, pathological gambling (PG), is likewise associated with an enhanced response to stress.
Methods: We induced stress by injecting yohimbine (0.2–0.3 mg/kg, IV), an alpha-2 adrenoceptor antagonist that elicits
stress-like physiological and psychological effects in humans and in laboratory animals, to four subjects with PG and to five
non-gamblers mentally healthy control subjects. Their fMRI brain responses were assessed along with subjective stress and
gambling urges ratings.
Results: Voxelwise analyses of data sets from individual subjects, utilizing generalized linear model approach, revealed
significant left amygdala activation in response to yohimbine across all PG subjects. This amygdala effect was not observed
in the five control individuals. Yohimbine elicited subjective stress ratings in both groups with greater (albeit not statically
significantly) average response in the PG subjects. On the other hand, yohimbine did not induce urges to gamble.
Conclusions: The present data support the hypothesis of brain sensitization to pharmacologically-induced stress in PG.
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Introduction
As legalized gambling activities are rapidly expanding in our
society so do gambling-related public health problems [1]. The
overall lifetime prevalence of problem and/or pathological
gambling (PG) in the general adult population is about 5% [2,3]
and its annual cost to the American society as a result of crime,
decreased productivity and bankruptcies approximates $54 billion
[4]. These figures likely underestimate the problems associated
with PG because this is a more ‘silent’ addiction without
characteristic symptoms of intoxication, needles’ marks, or
overdose, and therefore may only become apparent relatively late
in the addiction process with the emergence of devastating and
irreversible consequences, including attempted suicide in up to
24% of untreated individuals [4–6]. Hence, to improve diagnosis
and treatment of PG it is important to identify its objective
markers and their underlying neurobiology.
There is evidence that PG is associated with heightened stress
responses. For example, gambling-related activities or exposure to
gambling-related cues increases physiological stress responses like
heart rate, skin conductance and norepinephrine concentrations in
plasma and in cerebrospinal fluid [7–16]. There is also evidence
that stress exposure causes gambling urges that may precipitate
‘‘relapse’’ to gambling [17–20]. Thus, like in drug addiction
[21–23], stress can precipitate and exacerbate the maladaptive
addictive behavior (gambling) and engagement in the addictive
behavior or exposure to cues associated with maladaptive behavior
(e.g., a slot machine) can lead to exaggerated or sensitized
activation of the brain stress systems [20].
We have previously evaluated psychosocial stress levels in
individuals with PG and found heightened scores across all
measures; additionally, greater perceived severity and amount of
daily stressors was associated with more urges to gamble [20].
Here, we further evaluated whether PG is associated with
enhanced stress response by using yohimbine in conjunction with
blood-oxygen-level dependent (BOLD) pharmacological magnetic
resonance imaging (phMRI).
Yohimbine is an FDA-approved medication (oral formulation) for
thetreatmentofmaleerectiledysfunction.Itisaprototypicalalpha-2
adrenoceptor antagonist that has been used in numerous studies to
induce stress- and anxiety-like states in both humans and laboratory
animals [24,25]. In addition to its actions on the alpha-2 adrenergic
systems, yohimbine also affects D2, alpha-1, 5HT1a, and benzodi-
azepine receptors [26–28]. However, termination of yohimbine’s
effects by alpha-2 agonists, clonidine and lofexidine, and replication
of these effects by the selective alpha-2 adrenoceptor antagonist, RS-
79948-197,rendersnon alpha-2receptors’-related effects an unlikely
mechanisms of yohimbine’s stressogenic action [27,28].
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among its various structures, it is possible on a theoretical basis to
construct a lengthy list of brain regions, engaged by yohimbine-
induced stress, activity in which could be altered in PG. In this
study the amygdala was given a priori emphasis because blockade of
presynaptic alpha-2 adrenoceptor leads to subjective stress
responses [29] resulting from norepinephrine releases within the
amygdala [30–32], which is also engaged by gambling cues
reactivity [33] and by drug craving [34] in respective subjects with
PG and with drug dependence. With these considerations in mind,
it was hypothesized that, in comparison in healthy subjects, PG
individuals would display amygdala hyperresponsivity to yohim-
bine.
Methods
Subjects
Participants of this pilot proof of concept/feasibility study
comprised of four subjects [mean age (standard deviation, SD):
40.6 (13.0) years; 2 males and 2 females; 3 Caucasian and 1
African-American; weight: 80.4 (9.8) kg] meeting the Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edition, Text
Revision (DSM-IV-TR [35]) criteria for PG and for no other Axis
I DSM-IV-TR diagnosis. The control subjects were five mentally
healthy individuals [age: 31.0 (9.3) years; 4 males and 1 female, 3
Caucasian and 2 African-American; weight: 74.5 (9.3) kg] who
were free from any type of gambling problems. There were no
significant group differences in age (t=1.06; df=7; p=0.32), in
weight (t=0.93; df=7; p=0.32) and in gender distribution
(p=0.52; two-tailed Fisher’s exact test).
The subjects were diagnosed using a best estimate format,
involving all available sources of information, including clinical
history, interview and the Structured Clinical Interview for DSM-
IV [36], and the South Oaks Gambling Screen (SOGS [37]). This
research was approved for safety and ethics by the Institutional
Review Board of McLean Hospital. The participants were
recruited by newspaper advertisement and underwent clinical
assessments in return for a participation fee after providing a
written informed consent to the McLean Hospital Institutional
Review Board-approved protocol.
All subjects were in good physical health, without any history of
head injury, loss of consciousness, brain tumor, seizures or
cerebrovascular accident, as determined by neurological screening
and by the Cornell Medical Index Health Questionnaire [38].
Recent drug and alcohol consumption was ruled out by negative
results on urine toxicology screen and breathalyzer.
Procedure
After completion of the clinical assessments and medical work
up, the subjects reported for the procedure at the McLean Brain
Imaging Center after having fasted and refrained from alcohol,
tobacco, caffeine and physical activity for at least 10 h. One h
before the imaging session, an intravenous catheter was placed
into an antecubital vein for yohimbine infusion and was kept
patent with a slow isotonic saline drip.
To date, numerous clinical studies employed intravenous
yohimbine as a pharmacological stressor in neuroimaging and in
clinical studies involving healthy subjects and psychiatric patients.
The dose of yohimbine in these studies ranged between 0.125 mg/
kg [39] to 0.4 mg/kg [40–43]. To explore potential dose-response
relations, on the present study, two healthy controls were
administered yohimbine at 0.3 mg/kg while the remainder of
healthy controls and all PG subjects received yohimbine at
0.2 mg/kg.
Yohimbine was injected 5 min into a 30-min long scan in a
single-blinded fashion. Four 2 ml yohimbine infusions were given
over ten min (one control subject received the yohimbine infusion
over 6 min), with each infusion lasting 20 sec. The onset of each
infusion was separated by a 2-min interval. Continuous hemody-
namic monitoring was performed and an advanced cardiac life
support certified physician was present throughout the course of
the study.
Analog scales for subjective ratings were projected via a
LabView program and a back projection television system outside
the Faraday shield of the scanner. The subjects rated their
subjective measures of stress and gambling urges on a continuous
Likert-type scale of 0 (none) to 12 (extreme). Ratings were initiated
one min pre-infusion and collected once per min until 20 minutes
post-infusion.
Image acquisition
Scans were performed on a 3-Tesla Siemens Trio MR Imaging
System (Siemens AG, Erlangen, Germany). A 3-plane scout scan
(conventional FLASH sequence with isotropic voxels of 2.8 mm)
was acquired. This was used for prescription of the fMRI image
stack (gradient echo planar imaging [EPI], repetition time/echo
time=2000/30 msec, 220 mm6220 mm field of view [FOV], 30
3-mm coronal slices starting from the anterior pole, no gap, right-
left readout, 64664 pixel, full k-space acquisition, no sensitivity
encoding [SENSE] acceleration; pulse sequence-enhanced version
of the Siemens epibold; total acquisition time 964: 04 min).
Automatic second-order shimming was performed over the fMRI
imaging volume before acquisition. After the functional scans,
subjects had a conventional T1 scan performed on the same
functional prescription and therefore with identical susceptibility
distortion (68 T1 weighted coronal slices, FOV=220 mm
6220 mm, 2566256 pixel, 3-mm thick were acquired covering
the whole brain, ‘‘matched warped’’) [44] and a standard T1
weighted magnetization prepared rapid gradient echo (MPRAGE)
three-dimensional (FOV=256 mm6256 mm6170 mm, 2566256
6128) for anatomic segmentation and parcellation.
Image analysis
The image analyses were conducted after the completion of
data collection from all participants. Functional MRI images
were aligned to the high-resolution T1 weighted MPRAGE
images in two steps with FMRIB’s Linear Image Registration
Tool (FLIRT). Instead of using a conventional high-signal-to-
noise-ratio EPI image for the intermediate, we employ a high-
resolution, T1-weighted ‘‘match-warped’’ EPI image that in-
creases the precision of the alignment between the functional
dataset and the high-resolution MPRAGE [44]. The MPRAGE
was then aligned to Montreal Neurological Institute (MNI) space
with FLIRT.
Data processing was performed with FSL release 4.0 (FMRIB
Analysis Group, Oxford University, United Kingdom; http://
www.fmrib.ox.ac.uk.ezp-prod1.hul.harvard.edu/fsl/), specifically
FEAT version number 5.92. Preprocessing procedures included
the following steps. First, image spikes were detected by FSL’s
outlier detection program (fsl_motion_outliers) and used as
covariates of no interest in the statistical analysis. Second, all
images within a scan were aligned to image #230 (in the middle),
with mcflirt [45], with 6 degrees of freedom. If the maximum
Euclidean deviation from this reference exceeded 3.0 mm (the
smaller voxel dimension), the scan was discarded. Third, non-
brain tissue was removed. Fourth, spatial filtering was performed,
with a Gaussian kernel with 5-mm full width half maximum.
Yohimbine in Pathological Gamblers
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over all voxels and images was fixed at 10000.
phMRI infusion model (Figure 1)
Based on a prior report in the literature, following intravenous
infusion of yohimbine (0.25–0.5 mg/kg) in healthy subjects, the
distribution is rapid, the elimination half-life is 0.25–2.5 h and
norepinephrine increases 3-fold within 15 minutes [46].
Voxelwise data analyses were carried out in the similar fashion
to the previously reported by our group on an phMRI study [47].
Statistical maps were generated using a generalized linear model
approach with two possible responses of interest: a gradual
increase in activation (Ramp) and a rapid onset of activation
followed by a gradual decay (Decay). An additional response of
interest was generated through appropriate contrasts to obtain a
step-wise response once the injection of yohimbine begins. The full
model also included motion parameters estimates and spikes’
temporal appearance as covariates of no interest.
We used a mixture of Gaussian distributions, the number and
parameters of each were optimally determined. Statistical
thresholds were determined utilizing a mixture model approach
[48,49]. Each voxel had 3 probabilities assigned to belong to one
of these classes: deactivation, null hypothesis, and activation class.
Each voxel had its p-value corrected, that is to say, thresholded so
that the posterior probability associated with the activation class
was 0.5 or larger. For standard presentation, statistical maps were
transformed into the MNI-standard brain space. The amygdala
was identified from the Oxford-Harvard probabilistic atlas issued
with FSL’s software package.
Results
Subjective ratings
Mean baseline subjective stress (i.e., distress) rating was 0 for
pathological gamblers and 0.2 (1.1) for healthy controls,
respectively. Throughout the 20 min following yohimbine admin-
istration, PG and healthy subjects demonstrated respective
increases in subjective stress ratings to 4.0 (5.4) and 2.4 (2.1) thus
yielding mean change from the baseline (peak value minus
baseline value) of 4.0 (5.4) and 2 (2.2). The mean group difference
in the stress ratings’ changes was 1.8 with pooled SD of 3.4,
corresponding to a medium effect size of d=0.53 SD. To achieve
80% power to detect stress ratings differences of this magnitude at
p,0.05 would require n=45 subjects per cell.
To determine effects of yohimbine on stress self-ratings, a one-
way analysis of variance (ANOVA) with a repeated-measures
design was conducted. Diagnosis (PG and healthy subjects) was the
grouping factor and Drug (pre- and post yohimbine) was the
within-subjects factor. This ANOVA resulted in a significant drug
effect (F=5.83; df=1; p,0.05) but no significant group effect
(F=0.25; df=1; p=0.63) or drug by group interaction (F=0.53;
df=1,7; p=0.49). Repeating the latter analysis after excluding the
two subjects who received 0.3 mg/kg of yohimbine (both in the
control group) revealed a trend for significant drug effect (F=4.30;
df=1, 7; p,0.09), which would have been statistically significant
had this result been predicted a priori.
Yohimbine produced no meaningful effect on subjective self-
reports of gambling urges in PG subjects [pre- and post-yohimbine
values: 1.3 (1.0) and 1.0 (0.8)].
Figure 1. phMRI of Yohimbine. Top: Yohimbine Infusion Procedure. Following a 5 min baseline, yohimbine was infused in four separate
infusions, each infusion lasting 20 sec, and with an interinfusion interval of 2 min, as shown in the box (see Text). Middle: Plasma levels of
Yohimbine. Based on prior reports [77] doses of yohimbine reach maximal levels immediately after intravenous infusion and remain high for at least
20 min. Bottom: Plasma levels of norepinephrine rapidly follow yohimbine infusions [78]. These levels also remain high for the duration of the phMRI
data acquisition.
doi:10.1371/journal.pone.0031118.g001
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The MNI x, y, and z coordinates of the peak voxel in the left
amygdala cluster of activation (corrected p,0.001) along with the
cluster volume for each PG subject are presented in Table 1.
After an infusion of yohimbine (0.2 mg/kg), left amygdala
activation was observed for each subject diagnosed with PG
(Figure 2). This is indicated by significant BOLD responses that
correspond to a gradual increase in activation. The other models
of a rapid onset and decay or a step-wise response were not
apparent. Healthy controls did not display significant amygdala
activation at the same dose and even at the 0.3 mg/kg dose (n=2).
No significant deactivation was observed at the individual level for
the two groups. The two-tailed Fisher’s exact test, performed to
compare the proportion of subjects with yohimbine-induced
amygdala activation (4/4 vs. 0/5), revealed a significant group
difference (p=0.008).
Other brain regions that were significantly activated in
individual PG subjects included right frontal pole and left
hippocampus. The following areas were significantly activated in
single healthy control subjects: left putamen, left caudate, right
pallidum, left anterior cingulate cortex and left frontal pole. None
of these areas of activations overlapped across the subjects.
Discussion
The major finding of this study was that pathological gamblers
had significantly greater yohimbine-induced activations in the left
amygdala region. A similar approach in substance use disorders
indicate that drug- and alcohol dependent patients are hypersen-
sitive to yohibine-induced stress as evidenced by their startle
hyperreflexia [40,50], their elevated stress hormones [40,51] and
the emergence of withdrawal-like symptomatology [41].
The present results extend our early work with psychometric
assessments in which we found increases in stress and negative
mood states in PG subjects [20]. Our data with yohimbine, an
alpha-2 adrenoceptor antagonist that activates both peripheral
and central noradrenergic systems [25], are also consistent with
prior reports of sympathetic hyperresponsivity in PG [11,12].
Together, our current and previous results suggest that PG is
associated with heightened reactivity to various types of stress and
that the left amygdala is involved in this association.
Another main finding in our study is that the enhanced fMRI
response to yohimbine in PG subjects was only observed in the left
amygdala. This laterality in response to stress may be consistent
Figure 2. Individual data set. Clusters of activation (colored; corrected p,0.001) from voxelwise analyses of the effects of yohimbine infusion
obtained from individual subjects projected onto a background (grayscale) representing subjects’ mean high-resolution anatomic image. Coordinates
of coronal slices are in accordance with the Montreal Neurological Institute (MNI) space. Please note: two healthy controls received yohimbine at
0.3 mg/kg; the rest of the subjects were administered 0.2 mg/kg. PG-pathological gamblers; HC-healthy controls.
doi:10.1371/journal.pone.0031118.g002
Table 1. Individual clusters of amygdala activation in
pathological gamblers (corrected p,0.001).
Coordinates (mm) Z value Volume (mm
3)
X Y Z
PG_01 218 26 220 1.23 304
PG_02 222 0 218 1.13 112
PG_03 222 28 214 1.32 376
PG_04 222 2 218 1.22 496
The coordinates are taken from the MNI Brain Atlas. The origin of the
coordinates refers to the anterior commissure.
doi:10.1371/journal.pone.0031118.t001
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fMRI and positron emission tomography studies suggests that the
left amygdala is more likely to be activated than the right
amygdala during emotional tasks [52]. The procedure employed
here, however, does not allow firm separation of physiological and
emotional stress components involved in pathological gamblers’
amygdala activations. Answering this question would require an
exclusively emotional task that does not employ pharmacological
agents.
Methodological considerations
Under the current experimental conditions, yohimbine was an
effective stressor eliciting stress responses in both groups. The
failure to detect significant group differences in the subjective stress
reports may be secondary to the small sample size, that is to say,
the Type II error. Also, given the greater variability in stress
ratings in the PG group, in a larger sample the stress response
could be correlated with the change in BOLD signal in the
amygdala. On the other hand, some of the stress’ aspects may be
subliminal and not readily amenable for self-reports. For instance,
on a recent study, alcohol dependent patients showed heightened
hypothalamic-pituitary-adrenal axis’ responses to alcohol cues and
to a generic stressor, but only the former and not to the latter type
of the stimulus elevated subjective stress ratings [53].
Another caveat that should be considered in interpreting these
data pertains to the age confound as PG patients averaged 10
years older than healthy subjects. This is an unlikely confound as
there is a considerable amount of clinical data suggesting opposite
to our finding age-related declines in the amygdala function [54–
56]. Nonetheless, a study of an age-matched control group may be
warranted. Similar caveat is pertinent to the dose yohimbine as
two controls received a higher dose of 0.3 mg/kg even though
given the lack of amygdala activations in healthy people exposed
to 0.3 mg/kg of yohimbine, a compelling a fortiori argument could
be that such a response will be also absent with 0.2 mg/kg. These
and other important factors that were not a part of the present
study design (e.g., plasma yohimbine concentration) may need to
be assessed in future studies.
Contrary to the prior reports on yohimbine-induced craving in
opioid- [41] and alcohol- [57] dependent subjects, participants in
the current experiment reported no meaningful change in the level
of their gambling urges. It has been previously proposed that
gambling urges and drug craving are analogous phenomena [58–
60], but our findings perhaps suggest otherwise. More yohimbine
studies, matching drug dependent patients and pathological
gamblers by the severity of their addiction, may be needed to
ascertain potential gambling urges insensitivity to noradrenergic
stimulation. On the other hand, an important factor, not
addressed by the present design, which could yield information
bearing upon elucidation of gambling urges’ triggers, is the
expectancy context. Thus, the fMRI scanner or the laboratory
context may mask stress-related gambling urges while gambling
cues or knowledge that gambling opportunities are available
during or after the infusion could produce the opposite effect [61].
A limitation with this study’s design is its inability to resolve the
risk factor versus acquired origin of the hyperresponsive circuitry
in PG. While it is tempting to speculate that similarly to drugs of
abuse [21,62–64] gambling activities contribute to the brain stress
sensitization, an alternative interpretation is also plausible. Thus,
persons with high stress sensitivity (potentially due to prior stressful
experiences) may have greater propensity for development of
gambling addiction owing to stress-related neuroadaptations in the
dopaminergic circuits [65]. Regardless of the origin, a feedforward
interaction could be a possible outcome wherein gambling and
gambling-related cues trigger stress responses while stress pro-
motes gambling.
Concluding remarks
The present findings together with sensitized brain metabolic
reactions to gambling-related stimuli [66,67] are reminiscent of a
cross-sensitization phenomenon observed in substance use disor-
ders. The latter term typically refers to a situation where prior
exposure to one stimulus (e.g., drug) increases subsequent response
to itself [68–71] and to a different stimulus (e.g., stress) [62–64]
and in the reversed order, enhancement of drug motivational
states e.g., craving [72,73] following prior stress exposure [65].
Indeed, the sensitized stress responses in PG are mostly
conspicuous in the context of gambling and gambling-related
cues [7–12], whereas stress is a key factor responsible for gambling
urges [20] inherent in the chronically relapsing nature of PG [17–
19]. This raises the possibility of overlapping and sensitized
neuropsychobiological systems engaged by stress- and gambling-
related stimuli in patients with PG. Such a testable hypothesis
could be evaluated in PG subjects by juxtaposing responses to
functional neuroimaging probes that reliably activate both brain
stress and motivational circuits.
Finally, it is noteworthy that stress-related noradrenergic system
has been implicated in the pathophysiology of impulsivity at large
[74] not just in PG, which is while considered by some to be a
prototype non pharmacological addiction [75,76] is actually
classified as an impulse control disorder [29]. Therefore it would
also be of interest to test whether the observed stress alterations are
generalizable to impulse control disorders as a class.
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